T. E. Witzig Et Al. , "Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma," AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10, 2017
Witzig, T. E. Et Al. 2017. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10 .
Witzig, T. E., Zinzani, P. L., Habermann, T. M., Tuscano, J. M., Drach, J., Ramchandren, R., ... Besisik, S.(2017). Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10.
Witzig, Thomas Et Al. "Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma," AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10, 2017
Witzig, Thomas E. Et Al. "Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma." AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10, 2017
Witzig, T. E. Et Al. (2017) . "Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma." AMERICAN JOURNAL OF HEMATOLOGY , vol.92, no.10.
@article{article, author={Thomas E. Witzig Et Al. }, title={Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma}, journal={AMERICAN JOURNAL OF HEMATOLOGY}, year=2017}